Intermittent Fasting Improves Cardiometabolic Risk Factors and Alters Gut Microbiota in Metabolic Syndrome Patients
Guo Y, Luo S, Ye Y, Yin S, Fan J, Xia M
The Journal of clinical endocrinology and metabolism · 153 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Key Research and Development Program of China
- Gobierno
- National Natural Science Foundation of China-Guangdong Joint Fund
- Subvenciones
- National Natural Science Foundation of China-Guangdong Joint Fund (U1801281); National Key Research and Development Program of China (2017YFC0907101); National Key Research and Development Program of China (2017YFC0907100)
Según 2 financiadores declarados.
Publicación
- Publicado
- 2020-10-05 · J Clin Endocrinol Metab · vol. 106 · número 1 · págs. 64–79
- Editorial
- Oxford University Press
- Citado
- 196 citas · más que el 99% de estudios similares · 9.4× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 49 trabajos
- Acceso
- Lectura gratuita
- Áreas de investigación
- Dietary Effects on Health · Gut microbiota and health · Diet and metabolism studies
- Palabras clave
- Metabolic syndrome, Gut flora, Medicine, Internal medicine, Physiology, Environmental health, Obesity, Immunology
- MeSH
- humans, cardiovascular diseases, treatment outcome, caloric restriction, fasting, body composition, adult, middle aged, china, female, male, obesity, abdominal, dysbiosis, gastrointestinal microbiome, metabolic syndrome, cardiometabolic risk factors
6 autores
- Yi Guo🇨🇳Sun Yat-sen University
- Shiyun Luo🇨🇳Sun Yat-sen University
- Yongxin Ye🇨🇳Sun Yat-sen University
- Songping Yin🇨🇳Sun Yat-sen University
- Jiahua Fan🇨🇳Sun Yat-sen University
- Min Xia🇨🇳 · autor de correspondenciaSun Yat-sen University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Context
Intermittent fasting (IF) is an effective strategy to improve cardiometabolic health.
Objective
The objective of this work is to examine the effects of IF on cardiometabolic risk factors and the gut microbiota in patients with metabolic syndrome (MS).
Design and setting
A randomized clinical trial was conducted at a community health service center.
Patients
Participants included adults with MS, age 30 to 50 years.
Intervention
Intervention consisted of 8 weeks of "2-day" modified IF.
Main outcome measure
Cardiometabolic risk factors including body composition, oxidative stress, inflammatory cytokines, and endothelial function were assessed at baseline and at 8 weeks. The diversity, composition, and functional pathways of the gut microbiota, as well as circulating gut-derived metabolites, were measured.
Results
Thirty-nine patients with MS were included: 21 in the IF group and 18 in the control group. On fasting days, participants in the IF group reduced 69% of their calorie intake compared to nonfasting days. The 8-week IF significantly reduced fat mass, ameliorated oxidative stress, modulated inflammatory cytokines, and improved vasodilatory parameters. Furthermore, IF induced significant changes in gut microbiota communities, increased the production of short-chain fatty acids, and decreased the circulating levels of lipopolysaccharides. The gut microbiota alteration attributed to the IF was significantly associated with cardiovascular risk factors and resulted in distinct genetic shifts of carbohydrate metabolism in the gut community.
Conclusion
IF induces a significant alteration of the gut microbial community and functional pathways in a manner closely associated with the mitigation of cardiometabolic risk factors. The study provides potential mechanistic insights into the prevention of adverse outcomes associated with MS.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.